Guggenheim Downgrades Ra Pharma (RARX) to Neutral
Tweet
Share
E-mail
Get Alerts RARX Hot Sheet
Price: $48.00 --0%
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
0 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Guggenheim analyst Yatin Suneja downgraded Ra Pharma (NASDAQ: RARX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.
Shares of Ra Pharma closed at $46.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Truist Securities Downgrades HashiCorp Inc (HCP) to Hold
- JPMorgan Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
